

Giancarlo Marenzi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9293172/publications.pdf>

Version: 2024-02-01

148
papers

8,628
citations

61945

43
h-index

45285

90
g-index

156
all docs

156
docs citations

156
times ranked

9607
citing authors

#	ARTICLE	IF	CITATIONS
1	The Impact of COVID-19 Pandemic on Scientific Research: an Upcoming New Wave?. <i>Journal of General Internal Medicine</i> , 2022, 37, 2553-2555.	1.3	10
2	Inflammation and left ventricular thrombosis after STEMI: Risk marker or risk factor?. <i>International Journal of Cardiology</i> , 2022, , .	0.8	0
3	Human monocyte-derived macrophages: Pathogenetic role in plaque rupture associated to systemic inflammation. <i>International Journal of Cardiology</i> , 2021, 325, 1-8.	0.8	3
4	Netrin-1 in Atherosclerosis: Relationship between Human Macrophage Intracellular Levels and In Vivo Plaque Morphology. <i>Biomedicines</i> , 2021, 9, 168.	1.4	7
5	Ischaemic and bleeding risk in cancer patients undergoing PCI: another brick in the wall. <i>European Heart Journal</i> , 2021, 42, 1035-1037.	1.0	5
6	Can the in-hospital mortality gap between STEMI patients with and without diabetes mellitus be reduced? The cardio-renal hypothesis. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 1516-1520.	1.1	1
7	ST-Segment Elevation Acute Myocardial Infarction Complicated by Cardiogenic Shock: Early Predictors of Very Long-Term Mortality. <i>Journal of Clinical Medicine</i> , 2021, 10, 2237.	1.0	4
8	Potential Relation between Plasma BDNF Levels and Human Coronary Plaque Morphology. <i>Diagnostics</i> , 2021, 11, 1010.	1.3	6
9	Plasma Exosome Profile in ST-Elevation Myocardial Infarction Patients with and without Out-of-Hospital Cardiac Arrest. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8065.	1.8	6
10	The Multifaceted Therapeutic Role of N-Acetylcysteine (NAC) in Disorders Characterized by Oxidative Stress. <i>Current Neuropharmacology</i> , 2021, 19, 1202-1224.	1.4	44
11	The Role of Glycemic Variability in Cardiovascular Disorders. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8393.	1.8	21
12	Acute kidney injury and in-hospital mortality in patients with ST-elevation myocardial infarction of different age groups. <i>International Journal of Cardiology</i> , 2021, 344, 8-12.	0.8	10
13	Mitochondrial Biomarkers in Patients with ST-Elevation Myocardial Infarction and Their Potential Prognostic Implications: A Prospective Observational Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 275.	1.0	4
14	Vitamin D and Cardiovascular Disease: Current Evidence and Future Perspectives. <i>Nutrients</i> , 2021, 13, 3603.	1.7	57
15	Acute Myocardial Infarction During the COVID-19 Pandemic: An Update on Clinical Characteristics and Outcomes. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 648290.	1.1	29
16	Iron deficiency in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. <i>International Journal of Cardiology</i> , 2020, 300, 14-19.	0.8	20
17	Rationale, experimental data, and emerging clinical evidence on early and preventive use of levosimendan in patients with ventricular dysfunction. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 310-316.	1.4	5
18	Prognostic impact of admission high-sensitivity C-reactive protein in acute myocardial infarction patients with and without diabetes mellitus. <i>Cardiovascular Diabetology</i> , 2020, 19, 183.	2.7	14

#	ARTICLE	IF	CITATIONS
19	Characteristics, Management, and Outcomes of Acute Coronary Syndrome Patients with Cancer. <i>Journal of Clinical Medicine</i> , 2020, 9, 3642.	1.0	14
20	A preprocedural risk score predicts acute kidney injury following primary percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 98, 197-205.	0.7	5
21	Impact of Glomerular Filtration Rate on the Incidence and Prognosis of New-Onset Atrial Fibrillation in Acute Myocardial Infarction. <i>Journal of Clinical Medicine</i> , 2020, 9, 1396.	1.0	7
22	Diabetes Mellitus and Acute Myocardial Infarction: Impact on Short and Long-Term Mortality. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1307, 153-169.	0.8	33
23	An In-hospital Pathway for Acute Coronary Syndrome Patients During the COVID-19 Outbreak: Initial Experience Under Real-World Suboptimal Conditions. <i>Canadian Journal of Cardiology</i> , 2020, 36, 961-964.	0.8	31
24	Time to treatment still matters in ST-elevation myocardial infarction: a call to maintain treatment effectiveness during the COVID-19 pandemic. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 408-409.	1.4	14
25	Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era. <i>European Heart Journal</i> , 2020, 41, 2083-2088.	1.0	716
26	High-volume hydration for the prevention of acute kidney injury after cardiac surgery. <i>Journal of Thoracic Disease</i> , 2019, 11, S1135-S1138.	0.6	1
27	Extended dual antiplatelet therapy after acute myocardial infarction. Current evidence and future perspectives. <i>Monaldi Archives for Chest Disease</i> , 2019, 89, .	0.3	2
28	Acute kidney injury: a common prognostic condition for different pathogenetic triggers?. <i>Journal of Thoracic Disease</i> , 2019, 11, E112-E114.	0.6	1
29	Biological profile of monocyte-derived macrophages in coronary heart disease patients: implications for plaque morphology. <i>Scientific Reports</i> , 2019, 9, 8680.	1.6	23
30	Activation of Nrf2/HO-1 Pathway and Human Atherosclerotic Plaque Vulnerability:an In Vitro and In Vivo Study. <i>Cells</i> , 2019, 8, 356.	1.8	30
31	Reduced Cardio-Renal Function Accounts for Most of the In-Hospital Morbidity and Mortality Risk Among Patients With Type 2 Diabetes Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. <i>Diabetes Care</i> , 2019, 42, 1305-1311.	4.3	15
32	Treatment of refractory vasospastic angina complicated by acute pulmonary oedema with levosimendan: a case report. <i>European Heart Journal - Case Reports</i> , 2019, 3, ytz002.	0.3	1
33	12(S)-Hydroxyeicosatetraenoic acid downregulates monocyte-derived macrophage efferocytosis: New insights in atherosclerosis. <i>Pharmacological Research</i> , 2019, 144, 336-342.	3.1	15
34	Trials in Dyslipidemic Patients Are Urged to Reconsider Comprehensive Lipid Management as a Means to Reduce Residual Cardiovascular Risk. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 960-967.	2.3	2
35	High-Sensitivity C-Reactive Protein and Acute Kidney Injury in Patients with Acute Myocardial Infarction: A Prospective Observational Study. <i>Journal of Clinical Medicine</i> , 2019, 8, 2192.	1.0	21
36	A new score based on the PEGASUS-TIMI 54 criteria for risk stratification of patients with acute myocardial infarction. <i>International Journal of Cardiology</i> , 2019, 278, 1-6.	0.8	10

#	ARTICLE	IF	CITATIONS
37	Association Between Haptoglobin Phenotype and Microvascular Obstruction in Patients With STEMI. JACC: Cardiovascular Imaging, 2019, 12, 1007-1017.	2.3	15
38	Acute Kidney Injury in Diabetic Patients With Acute Myocardial Infarction: Role of Acute and Chronic Glycemia. Journal of the American Heart Association, 2018, 7, .	1.6	23
39	Impact of Chronic Antiplatelet Therapy on Infarct Size and Bleeding in Patients With Acute Myocardial Infarction. Journal of Cardiovascular Pharmacology and Therapeutics, 2018, 23, 407-413.	1.0	2
40	Prognostic Value of the Acute-to-Chronic Glycemic Ratio at Admission in Acute Myocardial Infarction: A Prospective Study. Diabetes Care, 2018, 41, 847-853.	4.3	57
41	Proenkephalin for the early detection of acute kidney injury in hospitalized patients with chronic kidney disease. European Journal of Clinical Investigation, 2018, 48, e12999.	1.7	8
42	Acute kidney injury after lung cancer surgery. Lung Cancer, 2018, 123, 155-159.	0.9	35
43	QT-interval evaluation in primary percutaneous coronary intervention of ST-segment elevation myocardial infarction for prediction of myocardial salvage index. PLoS ONE, 2018, 13, e0192220.	1.1	7
44	Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2017, 69, 176-185.	1.2	47
45	High Urine Output With Matched Hydration for CI-AKI Prevention. JACC: Cardiovascular Interventions, 2017, 10, 364-366.	1.1	4
46	Extracorporeal Ultrafiltration for Fluid Overload in Heart Failure. Journal of the American College of Cardiology, 2017, 69, 2428-2445.	1.2	88
47	A multicenter feasibility study on ultrafiltration via a single peripheral venous access in acute heart failure with overt fluid overload. International Journal of Cardiology, 2017, 240, 253-257.	0.8	4
48	Renal replacement therapy in patients with acute myocardial infarction: Rate of use, clinical predictors and relationship with in-hospital mortality. International Journal of Cardiology, 2017, 230, 255-261.	0.8	12
49	Prognostic Stratification of Patients With ST-Segment Elevation Myocardial Infarction (PROSPECT). Circulation: Cardiovascular Imaging, 2017, 10, .	1.3	48
50	Vitamin D and acute myocardial infarction. World Journal of Cardiology, 2017, 9, 14.	0.5	50
51	Extracorporeal ultrafiltration for acute heart failure: patient selection and perspectives. Vascular Health and Risk Management, 2017, Volume 13, 449-456.	1.0	3
52	Brain natriuretic peptide in acute myocardial infarction. Journal of Cardiovascular Medicine, 2016, 17, 803-809.	0.6	4
53	The role of levosimendan in acute heart failure complicating acute coronary syndrome: A review and expert consensus opinion. International Journal of Cardiology, 2016, 218, 150-157.	0.8	60
54	B-type natriuretic peptide levels in patients with pericardial effusion undergoing pericardiocentesis. International Journal of Cardiology, 2016, 212, 318-323.	0.8	4

#	ARTICLE	IF	CITATIONS
55	Peri-angiography Hemofiltration to Reduce Mortality. , 2016, , 73-80.		0
56	Acute Kidney Injury Definition and In-Hospital Mortality in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. Journal of the American Heart Association, 2016, 5, .	1.6	19
57	Diagnostic and Prognostic Utility of Circulating Cytochrome <i>c</i> in Acute Myocardial Infarction. Circulation Research, 2016, 119, 1339-1346.	2.0	15
58	The AVOID-HF Trial: Points to Consider. JACC: Heart Failure, 2016, 4, 331.	1.9	1
59	Vitamin D Plasma Levels and In-Hospital and 1-Year Outcomes in Acute Coronary Syndromes. Medicine (United States), 2015, 94, e857.	0.4	45
60	Continuous Ultrafiltration in Acute Decompensated Heart Failure: Current Issues and Future Directions. American Journal of Cardiovascular Drugs, 2015, 15, 103-112.	1.0	7
61	A meta-analysis of randomized controlled trials on statins for the prevention of contrast-induced acute kidney injury in patients with and without acute coronary syndromes. International Journal of Cardiology, 2015, 183, 47-53.	0.8	48
62	Prognostic significance of serum creatinine and its change patterns in patients with acute coronary syndromes. American Heart Journal, 2015, 169, 363-370.	1.2	19
63	Acute kidney injury in patients with acute coronary syndromes. Heart, 2015, 101, 1778-1785.	1.2	85
64	How to balance risks and benefits in the management of CKD patients with coronary artery disease. Journal of Nephrology, 2015, 28, 403-413.	0.9	15
65	Ultrafiltration for congestive heart failure. Current Opinion in Cardiology, 2015, 30, 186-191.	0.8	2
66	Myocardial Infarct Size in Patients on Long-Term Statin Therapy Undergoing Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction. American Journal of Cardiology, 2015, 116, 1791-1797.	0.7	29
67	Post-procedural hemodiafiltration in acute coronary syndrome patients with associated renal and cardiac dysfunction undergoing urgent and emergency coronary angiography. Catheterization and Cardiovascular Interventions, 2015, 85, 345-351.	0.7	5
68	B-Type Natriuretic Peptide and Risk of Acute Kidney Injury in Patients Hospitalized With Acute Coronary Syndromes*. Critical Care Medicine, 2014, 42, 619-624.	0.4	18
69	Continuous Ultrafiltration for Congestive Heart Failure: The CUORE Trial. Journal of Cardiac Failure, 2014, 20, 9-17.	0.7	116
70	Extracorporeal ultrafiltration for heart failure: Focus on organ cross talk and clinical trials. Nephrologie Et Therapeutique, 2014, 10, 203-209.	0.2	7
71	Continuous ultrafiltration for congestive heart failure: the CUORE trial. Journal of Cardiac Failure, 2014, 20, 378.e1-9.	0.7	7
72	Incidence and Relevance of Acute Kidney Injury in Patients Hospitalized With Acute Coronary Syndromes. American Journal of Cardiology, 2013, 111, 816-822.	0.7	71

#	ARTICLE	IF	CITATIONS
73	Ultrafiltration in Refractory Heart Failure. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1658-1659.	1.2	2
74	Questing for Circadian Dependence in ST-Segmentâ€Elevation Acute Myocardial Infarction. <i>Circulation Research</i> , 2013, 112, e110-4.	2.0	35
75	Diagnostic Potential of Plasmatic MicroRNA Signatures in Stable and Unstable Angina. <i>PLoS ONE</i> , 2013, 8, e80345.	1.1	118
76	Chronic Kidney Disease in Acute Myocardial Infarction: Clinical Relevance and Novel Potential Fields of Investigation. <i>Contributions To Statistics</i> , 2013, , 123-136.	0.2	0
77	Identification and Predictive Value of Interleukin-6 ⁺ Interleukin-10 ⁺ and Interleukin-6 ^{âˆ™} Interleukin-10 ⁺ Cytokine Patterns in ST-Elevation Acute Myocardial Infarction. <i>Circulation Research</i> , 2012, 111, 1336-1348.	2.0	72
78	Considerations for early acute myocardial infarction rule-out for emergency department chest pain patients: the case of copeptin. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 243-53.	1.4	34
79	Serum vitamin D concentration status and its correlation with early biomarkers of remodeling following acute myocardial infarction. <i>Clinical Research in Cardiology</i> , 2012, 101, 771-772.	1.5	5
80	Renal Replacement Therapies for Prevention of Radiocontrast-induced Nephropathy: A Systematic Review. <i>American Journal of Medicine</i> , 2012, 125, 66-78.e3.	0.6	113
81	Contrast-induced nephropathy. <i>Internal and Emergency Medicine</i> , 2012, 7, 181-183.	1.0	12
82	Impact of mannose-binding lectin deficiency on radiocontrast-induced renal dysfunction: a post-hoc analysis of a multicenter randomized controlled trial. <i>BMC Nephrology</i> , 2012, 13, 99.	0.8	4
83	Sodium chloride vs. sodium bicarbonate for the prevention of contrast medium-induced nephropathy: a randomized controlled trial. <i>European Heart Journal</i> , 2012, 33, 2071-2079.	1.0	83
84	Prevention of Contrast Nephropathy by Furosemide With Matched Hydration. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 90-97.	1.1	196
85	An Intense and Short-Lasting Burst of Neutrophil Activation Differentiates Early Acute Myocardial Infarction from Systemic Inflammatory Syndromes. <i>PLoS ONE</i> , 2012, 7, e39484.	1.1	52
86	Chronic kidney disease in acute coronary syndromes. <i>World Journal of Nephrology</i> , 2012, 1, 134.	0.8	37
87	Circulating Levels of Dimethylarginines, Chronic Kidney Disease and Long-Term Clinical Outcome in Non-ST-Elevation Myocardial Infarction. <i>PLoS ONE</i> , 2012, 7, e48499.	1.1	20
88	High-Sensitivity C-Reactive Protein Is Within Normal Levels at the Very Onset of First ST-Segment Elevation Acute Myocardial Infarction in 41% of Cases. <i>Journal of the American College of Cardiology</i> , 2011, 58, 2654-2661.	1.2	61
89	N-Acetylcysteine in Kidney Disease. , 2011, , 367-388.		1
90	Author's reply to Acute hyperglycemia: Is really a new risk marker for contrast-induced nephropathy in patients with acute myocardial infarction without diabetes and normal renal function?. <i>American Heart Journal</i> , 2011, 162, e9.	1.2	1

#	ARTICLE	IF	CITATIONS
91	Gene expression profiling reveals multiple differences in platelets from patients with stable angina or non-ST elevation acute coronary syndrome. <i>Thrombosis Research</i> , 2011, 128, 161-168.	0.8	27
92	Kinetics of plasma SPB and RAGE during mechanical ventilation in patients undergoing major vascular surgery. <i>Respiratory Physiology and Neurobiology</i> , 2011, 178, 256-260.	0.7	12
93	N-Acetylcysteine for the Prevention of Acute Kidney Injury After Cardiac Surgery. <i>Journal of Clinical Pharmacology</i> , 2011, 51, 1603-1610.	1.0	4
94	Acute kidney injury in ST-segment elevation acute myocardial infarction complicated by cardiogenic shock at admission*. <i>Critical Care Medicine</i> , 2010, 38, 438-444.	0.4	137
95	Circulating Cytochrome c as Potential Biomarker of Impaired Reperfusion in ST-Segment Elevation Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2010, 106, 1443-1449.	0.7	14
96	Proteome of platelets in patients with coronary artery disease. <i>Experimental Hematology</i> , 2010, 38, 341-350.	0.2	37
97	Circulating CD4 ⁺ CD25 ^{hi} CD127 ^{lo} Regulatory T-Cell Levels Do Not Reflect the Extent or Severity of Carotid and Coronary Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 1832-1841.	1.1	125
98	Extracorporeal Fluid Removal in Heart Failure Patients. <i>Contributions To Nephrology</i> , 2010, 164, 173-198.	1.1	3
99	Acute hyperglycemia and contrast-induced nephropathy in primary percutaneous coronary intervention. <i>American Heart Journal</i> , 2010, 160, 1170-1177.	1.2	90
100	Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. <i>European Heart Journal</i> , 2010, 31, 2765-2773.	1.0	709
101	Contrast-Induced Nephropathy in Patients Undergoing Primary Angioplasty. , 2010, , 250-258.		0
102	Use of Levosimendan for Treatment of Cardiogenic Shock Associated With Electrical Storm. <i>Annals of Internal Medicine</i> , 2009, 150, 738.	2.0	1
103	Percutaneous Cardiopulmonary Support for Catheter Ablation of Unstable Ventricular Arrhythmias in High-Risk Patients. <i>Herz</i> , 2009, 34, 545-552.	0.4	42
104	High-dose N-acetylcysteine for the Prevention of Contrast-induced Nephropathy. <i>American Journal of Medicine</i> , 2009, 122, 874.e9-874.e15.	0.6	87
105	Contrast Volume During Primary Percutaneous Coronary Intervention and Subsequent Contrast-Induced Nephropathy and Mortality. <i>Annals of Internal Medicine</i> , 2009, 150, 170.	2.0	300
106	Intermittent Hemofiltration for Management of Fluid Overload and Administration of Contrast Media. , 2009, , 1276-1281.		0
107	Contrast-Induced Nephropathy. <i>Journal of Interventional Cardiology</i> , 2008, 21, 74-85.	0.5	89
108	Tissue Factor in Patients With Acute Coronary Syndromes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 947-953.	1.1	98

#	ARTICLE	IF	CITATIONS
109	Prophylactic hemodialysis for the prevention of contrast-induced nephropathy after coronary angiography. <i>Nature Clinical Practice Nephrology</i> , 2008, 4, 130-131.	2.0	0
110	N-acetylcysteine for prevention of acute renal failure in patients with chronic renal insufficiency undergoing cardiac surgery: A prospective, randomized, clinical trial*. <i>Critical Care Medicine</i> , 2008, 36, 81-86.	0.4	73
111	Improved clinical outcome after intracoronary administration of bone marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. <i>European Heart Journal</i> , 2007, 28, 2172-2173.	1.0	149
112	Impact of cardiac and renal dysfunction on in-hospital morbidity and mortality of patients with acute myocardial infarction undergoing primary angioplasty. <i>American Heart Journal</i> , 2007, 153, 755-762.	1.2	68
113	The Reply:. <i>American Journal of Medicine</i> , 2007, 120, e11.	0.6	0
114	Comparison of Two Hemofiltration Protocols for Prevention of Contrast-induced Nephropathy in High-risk Patients. <i>American Journal of Medicine</i> , 2006, 119, 155-162.	0.6	170
115	Hyperoxemic perfusion of the left anterior descending coronary artery after primary angioplasty in anterior ST-elevation myocardial infarction. <i>Catheterization and Cardiovascular Interventions</i> , 2006, 67, 859-865.	0.7	22
116	Management of Acute Coronary Syndromes in Patients with Renal Insufficiency. <i>Current Cardiology Reviews</i> , 2006, 2, 11-16.	0.6	4
117	Gas diffusion and alveolar-capillary unit in chronic heart failure. <i>European Heart Journal</i> , 2006, 27, 2538-2543.	1.0	209
118	N-Acetylcysteine and Contrast-Induced Nephropathy in Primary Angioplasty. <i>New England Journal of Medicine</i> , 2006, 354, 2773-2782.	13.9	560
119	Recent advances in the prevention of radiocontrast-induced nephropathy. <i>Current Opinion in Internal Medicine</i> , 2005, 4, 1-5.	1.5	11
120	Can contrast-induced nephropathy after percutaneous coronary intervention be accurately predicted with a risk score?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2005, 2, 80-81.	3.3	5
121	Noninvasive Measurement of Cardiac Output During Exercise by Inert Gas Rebreathing Technique: A New Tool for Heart Failure Evaluation. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1779-1781.	1.2	154
122	Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2004, 44, 1780-1785.	1.2	645
123	Circadian distribution of acute myocardial infarction by anatomic location and coronary artery involvement. <i>American Journal of Medicine</i> , 2004, 116, 24-27.	0.6	11
124	Continuous veno-venous hemofiltration for the treatment of contrast-induced acute renal failure after percutaneous coronary interventions. <i>Catheterization and Cardiovascular Interventions</i> , 2003, 58, 59-64.	0.7	38
125	The Prevention of Radiocontrast-Agent-Induced Nephropathy by Hemofiltration. <i>New England Journal of Medicine</i> , 2003, 349, 1333-1340.	13.9	460
126	Serum to urinary sodium concentration ratio is an estimate of plasma renin activity in congestive heart failure. <i>European Journal of Heart Failure</i> , 2002, 4, 597-603.	2.9	10

#	ARTICLE	IF	CITATIONS
127	Circulatory response to fluid overload removal by extracorporeal ultrafiltration in refractory congestive heart failure. <i>Journal of the American College of Cardiology</i> , 2001, 38, 963-968.	1.2	230
128	Sustained Benefit from Ultrafiltration in Moderate Congestive Heart Failure. <i>Cardiology</i> , 2001, 96, 183-189.	0.6	34
129	Cardiac and Renal Dysfunction in Chronic Heart Failure: Relation to Neurohumoral Activation and Prognosis. <i>American Journal of the Medical Sciences</i> , 2001, 321, 359-366.	0.4	26
130	Non-invasive measurement of stroke volume during exercise in heart failure patients. <i>Clinical Science</i> , 2000, 98, 545-551.	1.8	54
131	Non-invasive measurement of stroke volume during exercise in heart failure patients. <i>Clinical Science</i> , 2000, 98, 545.	1.8	15
132	Effects of simulated altitude-induced hypoxia on exercise capacity in patients with chronic heart failure. <i>American Journal of Medicine</i> , 2000, 109, 450-455.	0.6	69
133	Cardiomegaly as a possible cause of lung dysfunction in patients with heart failure. <i>American Heart Journal</i> , 2000, 140, A17-A21.	1.2	58
134	Lack of improvement of lung diffusing capacity following fluid withdrawal by ultrafiltration in chronic heart failure. <i>Journal of the American College of Cardiology</i> , 2000, 36, 1600-1604.	1.2	75
135	The influence of diastolic and systolic function on exercise performance in heart failure due to dilated cardiomyopathy or ischemic heart disease. <i>European Journal of Heart Failure</i> , 1999, 1, 161-167.	2.9	18
136	Exercise-induced hemoconcentration in heart failure due to dilated cardiomyopathy. <i>American Journal of Cardiology</i> , 1999, 83, 278-280.	0.7	27
137	Guidelines for the Management of Patients with Acute Myocardial Infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 1998, 5, 73-81.	1.0	19
138	Platelet Activity in the Early Stage of Acute Myocardial Infarction: Relation to Time of Presentation, Treatment with Either Tissue Plasminogen Activator or Streptokinase and Cyclooxygenase Inhibition. <i>Journal of Thrombosis and Thrombolysis</i> , 1998, 5, 65-71.	1.0	4
139	Thrombin activation and late restenosis after percutaneous transluminal coronary angioplasty. <i>American Heart Journal</i> , 1998, 135, 503-509.	1.2	9
140	Improvement of Alveolar Capillary Membrane Diffusing Capacity With Enalapril in Chronic Heart Failure and Counteracting Effect of Aspirin. <i>Circulation</i> , 1997, 95, 1930-1936.	1.6	133
141	Influence of ACE Inhibition on Fluid Metabolism in Chronic Heart Failure and Its Pathophysiologic Relevance. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 1996, 1, 279-286.	1.0	2
142	Evaluation of the dead space/tidal volume ratio in patients with chronic congestive heart failure. <i>Journal of Cardiac Failure</i> , 1995, 1, 401-408.	0.7	23
143	β_2 -Thromboglobulin plasma levels in the first week after myocardial infarction: Influence of thrombolytic therapy. <i>American Heart Journal</i> , 1994, 128, 472-476.	1.2	7
144	Sustained improvement in functional capacity after removal of body fluid with isolated ultrafiltration in chronic cardiac insufficiency: Failure of furosemide to provide the same result. <i>American Journal of Medicine</i> , 1994, 96, 191-199.	0.6	241

#	ARTICLE	IF	CITATIONS
145	Interrelation of humoral factors, hemodynamics, and fluid and salt metabolism in congestive heart failure: Effects of extracorporeal ultrafiltration. American Journal of Medicine, 1993, 94, 49-56.	0.6	129
146	Usefulness of excitable gap and pattern of resetting in atrial flutter for determining reentry circuit location. American Journal of Cardiology, 1991, 68, 492-497.	0.7	29
147	Effects of disopyramide on cycle length, effective refractory period and excitable gap of atrial flutter, and relation to arrhythmia termination by overdrive pacing. American Journal of Cardiology, 1989, 63, 812-816.	0.7	23
148	Facilitating influence of disopyramide on atrial flutter termination by overdrive pacing. American Journal of Cardiology, 1988, 61, 1046-1049.	0.7	24